These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 26856969)

  • 1. Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.
    McDowell GC; Pope JE
    Neuromodulation; 2016 Jul; 19(5):522-32. PubMed ID: 26856969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Considerations and methodology for trialing ziconotide.
    Burton AW; Deer TR; Wallace MS; Rauck RL; Grigsby E
    Pain Physician; 2010; 13(1):23-33. PubMed ID: 20119460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability.
    Pope JE; Deer TR
    Neuromodulation; 2015 Jul; 18(5):414-20. PubMed ID: 25708382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bolus intrathecal injection of ziconotide (Prialt®) to evaluate the option of continuous administration via an implanted intrathecal drug delivery (ITDD) system: a pilot study.
    Mohammed SI; Eldabe S; Simpson KH; Brookes M; Madzinga G; Gulve A; Baranidharan G; Radford H; Crowther T; Buchser E; Perruchoud C; Batterham AM
    Neuromodulation; 2013; 16(6):576-81; discussion 582. PubMed ID: 23205907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options.
    Deer TR; Pope JE; Hanes MC; McDowell GC
    Pain Med; 2019 Apr; 20(4):784-798. PubMed ID: 30137539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.
    Sanford M
    CNS Drugs; 2013 Nov; 27(11):989-1002. PubMed ID: 23999971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Low Dose Ziconotide as First-Line Intrathecal Monotherapy.
    Prusik J; Argoff C; Peng S; Pilitsis JG
    Neuromodulation; 2017 Jun; 20(4):386-391. PubMed ID: 27492135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziconotide: a clinical update and pharmacologic review.
    Pope JE; Deer TR
    Expert Opin Pharmacother; 2013 May; 14(7):957-66. PubMed ID: 23537340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administering ziconotide and monitoring patients treated with ziconotide: expert opinions.
    Mitchell AA; Sapienza-Crawford AJ; Hanley KL; Lokey KJ; Wells L; McDowell GC; Stanton-Hicks M
    Pain Manag Nurs; 2013 Sep; 14(3):e84-94. PubMed ID: 23972874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ziconotide Trialing by Intrathecal Bolus Injections: An Open-Label Non-Randomized Clinical Trial in Postoperative/Posttraumatic Neuropathic Pain Patients Refractory to Conventional Treatment.
    Bäckryd E; Sörensen J; Gerdle B
    Neuromodulation; 2015 Jul; 18(5):404-13. PubMed ID: 25879804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal Ziconotide Infusion Therapy for Oncologic Refractory Neuropathic Pain: Case Report With High-Dose Intraventricular Ziconotide After 15 Years of Treatment.
    López-Millán JM; Coca-Gamito C
    Neuromodulation; 2024 Oct; 27(7):1251-1253. PubMed ID: 39078347
    [No Abstract]   [Full Text] [Related]  

  • 12. Italian registry on long-term intrathecal ziconotide treatment.
    Raffaeli W; Sarti D; Demartini L; Sotgiu A; Bonezzi C;
    Pain Physician; 2011; 14(1):15-24. PubMed ID: 21267038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Term Outcomes of a High-Volume, Low-Concentration Bolus Starting Dose Technique With Ziconotide: A Case Series.
    Lindley D
    Neuromodulation; 2021 Oct; 24(7):1209-1214. PubMed ID: 34252245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Oct; 44(10):478-83. PubMed ID: 17063978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain.
    Wallace MS
    Expert Rev Neurother; 2006 Oct; 6(10):1423-8. PubMed ID: 17078783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM).
    Deer T; Rauck RL; Kim P; Saulino MF; Wallace M; Grigsby EJ; Huang IZ; Mori F; Vanhove GF; McDowell GC
    Pain Pract; 2018 Feb; 18(2):230-238. PubMed ID: 28449352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.
    Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M
    Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrathecal ziconotide for refractory chronic pain.
    Lynch SS; Cheng CM; Yee JL
    Ann Pharmacother; 2006; 40(7-8):1293-300. PubMed ID: 16849624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrathecal ziconotide for the treatment of chronic pain: a collection of clinical experiences and literature review.
    De Negri P; Mastronicola C
    Eur Rev Med Pharmacol Sci; 2024 Aug; 28(15):4105-4110. PubMed ID: 39194195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice.
    Alicino I; Giglio M; Manca F; Bruno F; Puntillo F
    Pain; 2012 Jan; 153(1):245-249. PubMed ID: 22082570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.